Pearson Sees 1.9M New U.S. Tech Jobs By 2028, Indicating Employment Shifts
Pearson predicts 1.9m new tech jobs in the U.S. by 2028, signaling major employment shifts.
STMicroelectronics Bought 369,000 Shares For Eur 9.41M To Fulfill Share Option Obligations
STMicroelectronics repurchased 369,000 shares (0.04% of capital) on Euronext Paris from Oct 14-18, 2024, for EUR 9.41M, to meet obligations under share option…
ArcelorMittal, ABB Partner To Reduce Power Systems’ Environmental Impact
TLDR: ArcelorMittal sent an email to Boris with a link to their latest announcement about partnering with ABB to reduce environmental impact. The…
Munich RE Expands In Europe
Munich Re is preparing to meet the growing demand for reinsurance protection in Europe by focusing on risk-sharing mechanisms, efficient market dynamics, and…
Update: Austria and Benelux Countries Issue Joint Stamp That Comes With A Comic Book
New Crypto stamp "Drache" (German for dragon) released by Austrian Post, available in four countries, accompanied by a limited comic book with integrated…
CHMP Recommends Wainzua For EU Approval For Hereditary Amyloidosis
AstraZeneca's Wainzua (eplontersen) has been recommended for approval in the EU by CHMP for treating adult patients with hereditary transthyretin-mediated amyloidosis polyneuropathy.
Near Hackathon Deadline Extended
NEAR ecosystem updates: Hackathon prize pool exceeds $1m with extended deadline due to high demand.
Experian Aids Hispanics’ Financial Freedom, Relieving $10M Debt
Experian is promoting financial freedom for Hispanics by relieving $10 million in debt, partnering with NBCUniversal Telemundo and Prince Royce at the 2024…
Black Creek Share in Ontex Group Dropped Below 3% Voting Rights, Holding 2.97%
Ontex Group NV received a notification of significant shareholdings on October 16, 2024. Black Creek Investment Management Inc. disclosed holding 2,442,764 Ontex voting…
Novartis Kisqali Gets Positive Chmp Opinion For Reducing Recurrence In Breast Cancer
Novartis receives positive CHMP opinion for Kisqali® for adjuvant treatment of HR+/HER2- early breast cancer.